Cetuximab-induced pneumonitis in head and neck cancer patient

Oral Oncology

Volumn 48, Issue 6, 2012, Pages

  De Vos, F Y F L ^a   Driessen, C M L ^a   Jaspers, H C J ^a   Van Herpen, C M L ^a   Simons, B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CETUXIMAB; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE;

AGED; ALCOHOL ABUSE; ANTIBIOTIC THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG MEGADOSE; DYSPNEA; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPOXEMIA; INTERSTITIAL PNEUMONIA; LETTER; LEUKOCYTE COUNT; LUNG INFILTRATE; LUNG LAVAGE; MALE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; OROPHARYNX CARCINOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY TRACT INTUBATION; SMOKING HABIT; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; THORAX RADIOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; PNEUMONIA; TREATMENT OUTCOME;

EID: 84861585146     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.01.023     Document Type: Letter

References (3)

1. WHO. WHO disease and injury country estimates. 2009.
2. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New Engl J Med 354 6 2006 567 578
3. C.A. Naranjo, U. Busto, and E.M. Sellers A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 2 1981 239 245